Clinical Trial

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 3, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Neoadjuvant therapy is feasible in stage Ⅱ-Ⅲ melanoma, Carrelizumab combined with apatinib and temozolomide has synergistic antitumor effects and may improve pathological response.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-08-21; most recent amendment 2025-02-28.
Status change: Not Yet Recruiting → Recruiting 2023-07-18
Trial Details
NCT Number NCT05512481
Lead Sponsor Peking University Cancer Hospital & Institute
Conditions Melanoma, Acral Melanoma, Temozolomide, Apatinib, Camrelizumab, Neoadjuvant, Pathological Response
Enrollment 60 participants
Start Date 2022-09-13
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-03-03